Lenalidomide (PSH) Training Resources for Patient Safety Hub

Lenalidomide PSH training for Prescribers

Play video

View all videos

Lenalidomide PSH training for Pharmacists

Play video

Lenalidomide Educational Resources

Prescriber Resources

Lenalidomide Teva Prescribing Information

Lenalidomide PI

Lenalidomide Information Card for Patients and Healthcare Professionals

Download PDF

Lenalidomide Pregnancy Prevention Programme - Healthcare Professional Brochure

Download PDF

Lenalidomide Pregnancy Prevention Programme - Patient Education Brochure

Download PDF

Patient Safety Hub User Guide

Lenalidomide Pregnancy Prevention Programme

Download PDF

Patient Safety Hub

The Teva Patient Safety Hub is a digital Pregnancy Prevention Programme*. It enables healthcare professionals to register, initiate patients on treatment, complete and approve Prescription Authorisation Forms. The Programme is commissioned in alignment with the risk minimisation requirements set by the TGA for the prescribing and dispensing of Lenalidomide-Teva.

Coming soon!

*The Pregnancy Prevention Programme, which is a condition of the product licence, is designed to ensure that unborn babies are not exposed to lenalidomide to minimise the risk of teratogenicity.

Register to use the Patient Safety Hub

For healthcare professionals who prescribe or dispense lenalidomide.

Coming soon!

Technical Support

Our technical support team can help with technical issues about the Patient Safety Hub.

Tel: 1800 960 819 (AU)
Email:clientsupport@healthbeacon.com

Contact Us

Medical Information Service

Our Medical Information Service can help with enquiries about Teva medicines, devices and services. They can also provide copies of regulatory documents such as Patient Information Leaflets, or Summary of Product Characteristics.

Tel: 1800 288 382
Email: MedInfo.ANZ@tevapharm.com

Reporting Adverse Events / Pregnancy

Adverse events and pregnancy should be reported. Reporting forms and information can be found at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/. Adverse events should also be reported to Teva using the online reporting form, or email: Safety.Australia@tevapharm.com.

Tel: 1800 960 819 (AU)

Online Reporting Form

Order Inquiries or to book your training contact your local KAM:

Alessio De Giosa (NSW + NT + SA)
Mobile: 0401 826 274
Email: Alessio.DeGiosa@tevapharm.com

Carlie Mcconnell (VIC +TAS)
Mobile: 0402 257 291
Email: Carlie.Mcconnell@tevapharm.com

Clare Edwards (QLD + WA)
Mobile: 0412 284 372
Email: Clare.Edwards01@tevapharm.com

PBS Information: Authority Required
Refer to PBS Schedule for full authority information

PLEASE REVIEW PRODUCT INFORMATION (PI) BEFORE PRESCRIBING.
Full PI can be accessed at https://rss.medsinfo.com.au/tb/pi.cfm?product=tbplenal10822 or from Medical Information on 1800 AU TEVA (1800 288 382).

Date of preparation: April 2023, LENO-AU-00004